Article
A Triple-Mismatch Differentiating assay exploiting activation and trans cleavage of CRISPR-Cas12a for mutation detection with ultra specificity and sensitivity.
Biosensors & bioelectronics - 1 Jan 2025
Hu Yibo, Liao Yangwei, Pan Shutao, Zhou Jingcong, Wan Changqing, Huang Feiyang, Bai Yu, Lin Chen, Xia Qilong, Liu Zixi, Gong Jun, Nie Xiaoqi, Wang Min, Qin Renyi
Abstract excerpt
Liquid biopsy technology is non-invasive and convenient, and is currently an emerging technology for cancer screening. Among them, clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 12a (Cas12a) based nucleic acid detection technology has the advantages of high sensitivity, rapidity, and easy operation. However, CRISPR-Cas12a does not discriminate single-base mismatches...
Topics
- CRISPR-Cas Systems
- Humans
- Biosensing Techniques
- Mutation
- CRISPR-Associated Proteins
- Base Pair Mismatch
- Pancreatic Neoplasms
- Endodeoxyribonucleases
- Bacterial Proteins